Search
Maze Therapeutics Inc
MAZEAdd to Watchlist
23.920USD
+0.350+1.48%
Close 06/09, 16:00（ET）Quotes delayed by 15 min
1.19BMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
+1.48%
5 Days
-6.05%
1 Month
-8.11%
6 Months
-42.31%
Year to Date
-42.26%
1 Year
+85.00%
TradingKey Stock Score of Maze Therapeutics Inc
Currency: USD Updated: 2026-06-08Key Insights
Maze Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 390 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 63.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Maze Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Maze Therapeutics Inc Highlights
StrengthsRisks
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -10.01, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 53.41M shares, increasing 18.83% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 169.00 shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
63.500
Target Price
+161.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Maze Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Maze Therapeutics Inc Info
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Ticker SymbolMAZE
CompanyMaze Therapeutics Inc
CEOColoma (Jason V)
Websitehttps://www.mazetx.com/
Related Instruments
-0.47%
+2.10%
+0.63%
+1.04%
+0.08%
+1.86%
-0.36%
-2.06%
+0.21%
+2.83%
+1.64%
+0.61%
+1.88%
+1.18%
+2.25%
0.00%
+0.73%
+0.22%
+4.06%
-0.13%Popular Instruments
86.961
-2.773 (-3.09%)
290.360
-11.180 (-3.71%)
208.190
-0.450 (-0.22%)
4258.320
-71.300 (-1.65%)
517.620
-9.310 (-1.77%)
1646.780
+4.780 (+0.29%)
935.240
-14.040 (-1.48%)
364.240
+0.930 (+0.26%)
62182.720
-1272.770 (-2.01%)
396.620
-12.330 (-3.02%)
